Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Floriana Morgillo, Carminia Maria Della Corte, Morena Fasano, Fortunato Ciardiello, Floriana Morgillo, Carminia Maria Della Corte, Morena Fasano, Fortunato Ciardiello

Abstract

Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains unfavourable because of the occurrence of either intrinsic or acquired resistance. We reviewed the published literature and abstracts of oral and poster presentations from international conferences addressing EGFR-TKIs resistance mechanisms discovered in preclinical models and in patients with NSCLC. The molecular heterogeneity of lung cancer has several implications in terms of possible mechanisms of either intrinsic or acquired resistance to EGFR-targeted inhibitors. Several mechanisms of resistance have been described to EGFR-TKIs, such as the occurrence of secondary mutation (T790M, C797S), the activation of alternative signalling (Met, HGF, AXL, Hh, IGF-1R), the aberrance of the downstream pathways (AKT mutations, loss of PTEN), the impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism) and histological transformation. Although some of the mechanisms of resistance have been identified, much additional information is needed to understand and overcome resistance to EGFR-TKI agents. The majority of resistance mechanisms described are the result of a selection of pre-existing clones; thus, studies on the mechanisms by which subclonal alterations have an impact on tumour biology and influence cancer progression are extremely important in order to define the best treatment strategy.

Keywords: EGFR TKIs.

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Schematic representation of main EGFR-TKIs resistance mechanisms. Resistance to EGFR-TKIs can occur through different mechanisms either intrinsic or acquired. Known mechanisms are secondary resistance mutations occurring in the ATP-binding domain (such as T790M and C797S), mutation or amplification of bypass signallings (such as AXL, Hh, ERBb2, CRIPTO, etc), activating mutations in the downstream pathways (PI3K, AKT, MEK, RAF), low levels of mRNA or polymorphisms of the pro-apoptotic protein BIM, induction of a transcription programme for EMT and phenotypical changes, or induction of elevated tumour PD-L1 levels. EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; mRNA, messenger RNA; PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor.

References

    1. SEER Stat Fact Sheets: Lung and Bronchus Cancer. National Cancer Institute. .
    1. Lynch TJ, Bell DW, Sordella R et al. . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39. 10.1056/NEJMoa040938
    1. Paez JG, Jänne PA, Lee JC et al. . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500. 10.1126/science.1099314
    1. Mok TS, Wu YL, Thongprasert S et al. . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57. 10.1056/NEJMoa0810699
    1. Mitsudomi T, Morita S, Yatabe Y et al. . West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
    1. Maemondo M, Inoue A, Kobayashi K et al. . North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
    1. Zhou C, Wu YL, Chen G et al. . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42. 10.1016/S1470-2045(11)70184-X
    1. Han JY, Park K, Kim SW et al. . First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122–8. 10.1200/JCO.2011.36.8456
    1. Rosell R, Carcereny E, Gervais R et al. . Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
    1. Sequist LV, Yang JC, Yamamoto N et al. . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34.
    1. Wu YL, Zhou C, Hu CP et al. . Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213–22. 10.1016/S1470-2045(13)70604-1
    1. Yang JC, Wu YL, Schuler M et al. . Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141–51. 10.1016/S1470-2045(14)71173-8
    1. Kobayashi S, Boggon TJ, Dayaram T et al. . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92. 10.1056/NEJMoa044238
    1. Zhou W, Ercan D, Chen L et al. . Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070–4. 10.1038/nature08622
    1. Cross DAE, Ashton SE, Ghiorghiu S et al. . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046–61. 10.1158/-14-0337
    1. Soria J, Sequist LV, Goldman JW et al. . Interim phase 2 results of study CO-1686-008: a phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. Eur J Cancer 2014;50:199 10.1016/S0959-8049(14)70731-2
    1. Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. Lung Cancer 2016;93:59–68.
    1. Murakami H, Nokihara H, Shimizu T et al. . 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation. Eur J Cancer 2014;50:198.
    1. Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 2010;1804:559–66. 10.1016/j.bbapap.2009.12.010
    1. Costa DB, Yasuda H, Sng NY. Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR. J Clin Oncol 2012;30:110–12. 10.1200/JCO.2011.39.4486
    1. De Pas T, Toffalorio F, Manzotti M et al. . Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6:1895–901. 10.1097/JTO.0b013e318227e8c6
    1. Costa C, Molina MA, Drozdowskyj A et al. . The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or 35 chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014;20:2001–10. 10.1158/1078-0432.CCR-13-2233
    1. Ji H, Zhao X, Yuza Y et al. . Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad USA 2006;103:7817–22. 10.1073/pnas.0510284103
    1. Duan J, Wang Z, Bai H et al. . Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung. Thorac Cancer 2015;6:319–26. 10.1111/1759-7714.12204
    1. Faber AC, Corcoran RB, Ebi H et al. . BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011;1:352–65. 10.1158/-11-0106
    1. Park KS, Raffeld M, Moon YW et al. . CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J Clin Invest 2014;124:3003–15. 10.1172/JCI73048
    1. Jackman D, Pao W, Riely GJ et al. . Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357–60. 10.1200/JCO.2009.24.7049
    1. Gandara DR, Li T, Lara PN et al. . Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer 2014;15:1–6. 10.1016/j.cllc.2013.10.001
    1. Yun C-H, Mengwasser KE, Toms A V et al. . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070–5. 10.1073/pnas.0709662105
    1. Oxnard GR, Arcila ME, Sima CS et al. . Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616–22. 10.1158/1078-0432.CCR-10-2692
    1. Hata AN, Niederst MJ, Archibald HL et al. . Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 2016;22:262–9. 10.1038/nm.4040
    1. Yu HA, Tian SK, Drilon AE et al. . Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015;1:982–4.
    1. Niederst MJ, Hu H, Mulvey HE et al. . The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015;21:3924–33. 10.1158/1078-0432.CCR-15-0560
    1. Sequist LV, Waltman BA, Dias-Santagata D et al. . Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26 10.1126/scitranslmed.3002003
    1. Sutherland KD, Proost N, Brouns I et al. . Cell of origin of small lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011;19:754–64. 10.1016/j.ccr.2011.04.019
    1. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740–6. 10.1016/j.ceb.2003.10.006
    1. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277–9.
    1. Herbst RS, Prager D, Hermann R et al. . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892–9.
    1. Yauch RL, Januario T, Eberhard DA et al. . Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686–98.
    1. Zhang Z, Lee JC, Lin L et al. . Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852–60. 10.1038/ng.2330
    1. Della Corte CM, Bellevicine C, Vicidomini G et al. . SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer. Clin Cancer Res 2015;21:4686–97. 10.1158/1078-0432.CCR-14-3319
    1. Gianikopoulos B, Wellde H, Polkinghorn P et al. . Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired resistance to erlotinib [abstract]. Proceedings of the 15th World Conference on Lung Cancer; 2013 Oct 27–31; Sydney, Australia; 2013. Abstract nr 1426.
    1. Bai XY, Zhang XC, Yang SQ et al. . Blockade of Hedgehog signaling synergistically increases sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer cell lines. PLoS ONE 2016;11:e0149370 10.1371/journal.pone.0149370
    1. Engelman JA, Zejnullahu K, Gale CM et al. . PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924–32. 10.1158/0008-5472.CAN-07-1885
    1. Fan W, Tang Z, Yin L et al. . MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 2011;71:4494–505. 10.1158/0008-5472.CAN-10-2668
    1. Takezawa K, Pirazzoli V, Arcila ME et al. . HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012;2:922–33. 10.1158/-12-0108
    1. Shtiegman K, Kochupurakkal BS, Zwang Y et al. . Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007;26:6968–78. 10.1038/sj.onc.1210503
    1. Oxnard GR, Thress K, Paweletz C et al. . Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer. J Thorac Oncol 2015;10(Suppl 2):ORAL17.07.
    1. Morgillo F, Woo JK, Kim ES et al. . Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66:10100–11. 10.1158/0008-5472.CAN-06-1684
    1. Choi YJ, Rho JK, Jeon BS et al. . Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol 2010;66:381–8. 10.1007/s00280-009-1174-7
    1. Ware KE, Marshall ME, Heasley LR et al. . Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 2010;5:e14117 10.1371/journal.pone.0014117
    1. Ohashi K, Sequist LV, Arcila ME et al. . PNAS plus: lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 2012;109:E2127–33. 10.1073/pnas.1203530109
    1. Taniguchi K, Uchida J, Nishino K et al. . Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808–15.
    1. Akbay EA, Koyama S, Carretero J et al. . Activation of the PD-1 pathway contributes to immune escape in EGFR- driven lung tumors. Cancer Discov 2013;3:1355–63. 10.1158/-13-0310
    1. Rizvi NA, Chow LQM, Borghaei H et al. . Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC (abstract). J Clin Oncol 2014;32(Suppl):802283.
    1. Murtaza M, Dawson SJ, Tsui DW et al. . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108–12.
    1. Thress KS, Paweletz CP, Felip E et al. . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015;21: 560–2.
    1. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487–93. 10.1038/nrc3298

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅